SPRO Apr 2023 7.500 call
| Previous close | 0.4000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.6000 |
| Strike | 7.50 |
| Expiry date | 2023-04-21 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
- GlobeNewswire
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on January 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 16,000 restricted stock unit awards (RSUs) to
- Simply Wall St.
Spero Therapeutics (NASDAQ:SPRO) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 85%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders should be happy to see the share price up 18% in the last month...
- GlobeNewswire
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one me
